---
document_datetime: 2024-09-24 12:05:07
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/cegfila-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: cegfila-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 3.7674489
conversion_datetime: 2025-12-28 12:24:59.43542
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Cegfila

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                               |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0020               | Renewal of the marketing authorisation. | 27/06/2024                          | 22/08/2024                                  | SmPC and PL                      | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Cegfila in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| WS/2614            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS   | 14/03/2024   | n/a        |                        |                                   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------|
| IB/0018            | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                             | 04/09/2023   | n/a        |                        |                                   |
| IB/0017            | B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                                                                                                                                                                                                                     | 29/03/2023   | n/a        |                        |                                   |
| IG/1593            | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                         | 24/02/2023   | 06/02/2024 | SmPC, Labelling and PL |                                   |
| IB/0015            | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                   | 05/10/2022   | n/a        |                        |                                   |
| PSUSA/2326/ 202201 | Periodic Safety Update EU Single assessment - pegfilgrastim                                                                                                                                                                                                                                                                                                        | 29/09/2022   | n/a        |                        | PRAC Recommendation - maintenance |
| IG/1526            | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                                                                                                                                                                                                                                 | 23/06/2022   | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|           | procedure                                                                                                                                                                                                                                                      |            |            |             |                                                                                                                                                                                                        |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0012   | B.II.f.1.a.1 - Stability of FP - Reduction of the shelf life of the finished product - As packaged for sale                                                                                                                                                    | 15/10/2021 | 14/10/2022 | SmPC        |                                                                                                                                                                                                        |
| IB/0011   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   | 12/07/2021 | 29/09/2021 | SmPC and PL | To update Myelodysplastic syndrome and acute myeloid leukaemia in breast and lung cancer patients and product handling information following assessment of the same changes for the reference product. |
| IB/0008   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   | 08/07/2021 | 29/09/2021 | SmPC and PL |                                                                                                                                                                                                        |
| WS/2084   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS | 24/06/2021 | n/a        |             |                                                                                                                                                                                                        |
| IB/0009/G | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                         | 28/04/2021 | n/a        |             |                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           | - Change in the specification parameters limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                 | B.I.b.1.z and/or     |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|----------------------|
| IG/1363/G | This was an application for a group of variations. B.IV.1.b - Change of a measuring or administration device - Deletion of a device B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test                                                                                                                                                                                                                                         | 10/03/2021 | n/a        |                 | procedure is already |
| IG/1295/G | This was an application for a group of variations. A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 09/10/2020 | 29/09/2021 | Annex II and PL |                      |
| WS/1916   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                   | 08/10/2020 | 29/09/2021 | SmPC            |                      |

<div style=\"page-break-after: always\"></div>

|           | - Stability of FP - Extension of the shelf of the finished product - Biological/immunological product in accordance with an approved protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                        | B.II.f.1.b.5 life medicinal stability   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------|
| II/0004/G | This was an application for a group of variations. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of | 03/09/2020 | n/a        |                        | the AS and/or the                       |
| N/0003    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 17/04/2020 | 29/09/2021 | PL                     |                                         |
| T/0001    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 07/02/2020 | 28/02/2020 | SmPC, Labelling and PL |                                         |
| IAIN/0002 | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 06/02/2020 | 28/02/2020 | SmPC, Labelling and PL |                                         |